WO2017174046A1 - A formulation of ixazomib citrate form 3 - Google Patents
A formulation of ixazomib citrate form 3 Download PDFInfo
- Publication number
- WO2017174046A1 WO2017174046A1 PCT/CZ2017/000022 CZ2017000022W WO2017174046A1 WO 2017174046 A1 WO2017174046 A1 WO 2017174046A1 CZ 2017000022 W CZ2017000022 W CZ 2017000022W WO 2017174046 A1 WO2017174046 A1 WO 2017174046A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical formulation
- ixazomib citrate
- formulation according
- ixazomib
- packed
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Definitions
- the invention relates to a pharmaceutical formulation of the novel polymorphic form 3 of ixazomib citrate of formula I:
- Form 3 as compared to the hitherto known form 1 of ixazomib citrate of formula I, disclosed in the patent WO 2009/154737, has turned out to be a polymorphically more stable form, which also makes it more suitable for use in ixazomib citrate formulation.
- Ixazomib is a novel member of the group of proteasome inhibitors with a structure belonging to the group of peptide boronic acids, now also known under the commercial name of Ninlaro. Ixazomib citrate is currently approved for use in combination with lenalidomide and dexamethasone, intended for the treatment of patients with multiple myeloma after at least one prior therapy.
- ixazomib citrate compared e.g. to bortezomib is that thanks to stabilization of the boronic acid in the form of a mixed ester-anhydride with citric acid the substance can also be administered in the oral form.
- ixazomib citrate is the first and so far the only orally administered drug of this kind, used for the treatment of multiple myeloma.
- boronic acids are sometimes difficult to prepare in the pure form. In conditions that are favorable for dehydration, boronic acids form cyclic anhydrides and are often sensitive to light. Therefore, boronic acids are advantageously stabilized with a complexing agent, e.g. an a- or ⁇ -hydroxy acid (WO2009/154737), or by preparation of precursors with azanediylbis alcohols (WO 2012/177835, WO 2011/087822A1), which enhances their stability and makes it possible to prepare a drug form, suitable for oral administration. Ixazomib citrate and a method of its preparation was first described in the patent application WO 2009/154737.
- Boroxine III or its free boronic acid is subjected to a reaction with citric acid in a solvent at an elevated temperature; after cooling, the crystallized product is isolated by filtering.
- form 1 of formula I, or form 2 of formula II can be obtained, both characterized by NMR, MS, X-ray powder diffraction and the DSC (differential scanning calorimetry) and TGA (thermogravimetric analysis) methods
- Form 2 can also be prepared through a reaction of the compound III with citric acid and crystallization from various solvents (tetrahydrofuran, acetonitrile, methyl /so-butyl ketone, 2-methyltetrahydrofuran, acetone) and subsequent addition of the ethyl acetate as an antisolvent.
- solvents tetrahydrofuran, acetonitrile, methyl /so-butyl ketone, 2-methyltetrahydrofuran, acetone
- the principle of the invention is a pharmaceutical formulation containing ixazomib citrate in crystalline form 3 as the active ingredient and at least one pharmaceutically acceptable auxiliary substance.
- Form 3 is a new polymorphic form of ixazomib citrate of formula I and exhibits the characteristic reflections in an X-ray powder patterns with the use of CuKa radiation: 5.4; 10.9; 12.4; 18.7 and 22.6 ⁇ 0.2° 2-theta.
- the new form 3 of ixazomib citrate of formula I proved to be a chemically and polymorphically stable form of isomer I of ixazomib citrate in pre-formulation experiments. Contrary to that, form 1 of ixazomib citrate of formula I, indicated in the patent WO 2009/154737, turned out to be polymorphically unstable under certain conditions and its conversion to ixazomib citrate of form 2 of formula II was observed.
- the pharmaceutical formulation according to the invention is packed in air-tight packages as an AI/AI blister pack.
- the excipients are preferably processed in such a way as to have a low content of moisture, e.g. less than 4%.
- the present invention relates to preparation of the solid pharmaceutical dosage form comprising ixazomib citrate in crystalline form 3, which can preferably be packed into a gas non-permeable packaging.
- One embodiment of the present invention comprises a pharmaceutical formulation with ixazomib citrate form 3 with an acceptable stability.
- Pharmaceutical formulations are preferably packed into a gas non-permeable packaging.
- Preferred gas non- permeable packaging is AI/AI blister.
- a pharmaceutical formulation comprising ixazomib citrate form 3 typically comprises one or more excipients. Though in general various excipients could be used, it is especially favorable to use excipients with low amount of residual water.
- an excipient with low amount of residual water is defined as an excipient, which contains not more than 4% w/w of water.
- the water content can be measured by a loss on drying apparatus. An example of such apparatus is for example from the firm Sartorius. Amount of water is measured at conditions 105°C for 10 minutes.
- Suitable fillers that can be used in preparation of pharmaceutical formulation of ixazomib citrate form 3 may be selected from, but not restricted to calcium hydrogen phosphate, microcrystalline cellulose, monosaccharides, oligosaccharides and sugar alcohols like glucose, fructose, saccharose, lactose monohydrate, lactose anhydrous, mannitol, erythritol, sorbitol, maltitol, xylitol and lactitol, compressible sugar and mixtures thereof.
- Preferred fillers are microcrystalline cellulose, calcium hydrogen phosphate anhydrous, lactose and mannitol. Most preferred are mannitol and a low moisture microcrystalline cellulose containing no more than 4% w/w of water.
- the amount of filler used to prepare the composition comprising ixazomib citrate form 3 may comprise 40 - 99% in such a way that the sum of API, filler and all other excipients reaches 100% of the final composition.
- the other excipient, which may be used to prepare a pharmaceutical formulation comprising ixazomib citrate form 3 is glidant.
- Suitable glidants that can be used in preparation of pharmaceutical formulation of ixazomib citrate form 3 may be selected from, but not restricted to magnesium silicate, magnesium oxide, magnesium trisilicate, colloidal silicon dioxide, hydrophobic colloidal silica, sodium stearate, talc and mixtures thereof.
- Preferred glidants are colloidal silicon dioxide and talc.
- the amount of glidant used to prepare the composition comprising ixazomib citrate form 3 may be 0.1 - 0%.
- the other excipient, which may be used to prepare a pharmaceutical formulation comprising ixazomib citrate form 3 is lubricant.
- Suitable lubricants that can be used in preparation of pharmaceutical formulation of ixazomib citrate form 3 may be selected from, but not restricted to hydrogenated castor oil, light mineral oil, myristic acid, palmitic acid, zinc stearate, stearic acid, hydrogenated vegetable oil, polyethylene glycol, glyceryl monostearate, glyceryl palmitostearate, sodium lauryl sulfate, sodium stearyl fumarate, magnesium stearate and mixtures thereof.
- Preferred lubricants are stearic acid and magnesium stearate.
- the amount of lubricants used to prepare the composition comprising ixazomib citrate form 3 may be 0.1 - 10%.
- a pharmaceutical formulation comprising ixazomib citrate form 3 may include also other excipients.
- excipients that can be used in preparation of pharmaceutical formulation of ixazomib citrate form 3 may be selected from binders, surfactants, disintegrants etc.
- a pharmaceutical formulation comprising ixazomib citrate form 3 is typically an encapsulated product.
- Suitable capsule shell materials used for encapsulation of pharmaceutical formulation of ixazomib citrate form 3 may be selected from both animal as well as vegetable origin.
- Some non-binding examples of capsule shell materials of animal origin may be selected from animal protein materials like gelatin.
- Some non-binding examples of capsule shell materials of vegetable origin may be selected from plant polysaccharides like hydroxypropyl methylcellulose, carrageenan and modified forms of starch.
- Figure 1 X-ray powder pattern of ixazomib citrate of form 3.
- Mobile phase A 0.05 mol/l acetic acid, pH adjusted with an ammonia solution to 5.0
- Sample 5 mg of a sample of the substance is dosed into a 10ml preparation: volumetric flask and dissolved in 2 ml of methanol. The flask is filled with water up to the line and stirred.
- a 10 mm mask and a 1/4° fixed anti-dispersion slit were used.
- the irradiated area of the sample is 10 mm, programmable divergence slits were used.
- For the correction of the secondary array 0.02 rad Soller slits and a 5.0 anti-dispersion slit were used.
- the measurement was carried out with a flat sample applied onto a Si plate.
- the records of the differential scanning calorimetry (DSC) were measured using a DSC Pyris 1 device made by the company Perkin Elmer.
- the sample charge in a standard Al pot was between 3 and 4 mg and the heating rate was 10°C/min.
- the temperature program that was used consists of 1 min of stabilization at the temperature of 20°C and then of heating up to 250°C at the heating rate of 10°C/min.
- As the carrier gas 4.0 N2 was used at the flow of 20 ml/min.
- thermogravimetric analysis TGA 6 device made by the company Perkin Elmer.
- the sample charge in a corundum pot was 15-17 mg and the heating rate was 10°C/min.
- the temperature program that was used consists of 1 minute's stabilization at the temperature of 20°C and then of heating up to 300°C at the heating rate of 10°C/min.
- As the carrier gas 4.0 N2 was used at the flow of 20 ml/min.
- the XRPD pattern is shown in Fig. 1 , the characteristic peaks are presented in Table 1.
- the record is shown in Fig. no. 2 in the Appendix.
- the TGA record indicates a weight loss in the temperature range of 20 to 200°C of approx. 1.3%.
- Ixazomib citrate form 1 was mixed with microcrystalline cellulose, standard moisture and packed into a standard polyethylene (PE) bag.
- PE polyethylene
- the bag was put into the stress testing chamber for 7 days at 80°C and 75% relative humidity. After 7 days the amount of total impurities were measured by HPLC in order to analyze chemical purity. In addition, in order to analyze physical stability of polymorph, XRPD analysis was performed.
- the standard polyethylene bag did not exhibit enough protection. High amount of impurities were formed (12.1%) and in addition, polymorphic form changed from form 1 into form 2. Microcrystalline cellulose, standard moisture in combination with standard polyethylene packaging does not exhibit adequate protection of ixazomib citrate.
- Ixazomib citrate form 1 was mixed with microcrystalline cellulose, standard moisture and packed into AI/AI bag.
- the bag was put into the stress testing chamber for 7 days at 80°C and 75% relative humidity. After 7 days the amount of total impurities were measured by HPLC in order to analyze chemical purity.
- XRPD analysis was performed. Significant chemical degradation and polymorphic transformation were observed similar as the same formulation mixture packed in PE. mg/bag
- Microcrystalline cellulose standard moisture 86.00
- Example 1 Ixazomib citrate form 3 was mixed with microcrystalline cellulose, standard moisture and packed into AI/AI bag. The bag was put into the stress testing chamber for 7 days at 80°C and 75% relative humidity. After 7 days the amount of total impurities were measured by HPLC in order to analyze chemical purity. In addition, in order to analyze physical stability of polymorph, XRPD analysis was performed.
- Ixazomib citrate form 1 was mixed with microcrystalline cellulose, low moisture and packed into AI/AI bag. The bag was put into the stress testing chamber for 7 days at 80°C and 75% relative humidity. After 7 days the amount of total impurities were measured by HPLC in order to analyze chemical purity. In addition, in order to analyze physical stability of polymorph, XRPD analysis was performed. Comparing HPLC and XRPD data from table below with those for comparative example 1 , it seems that using of low moisture microcrystalline cellulose provides formulation with better chemical and physical stability
- Example 2 Ixazomib citrate form 3 was mixed with microcrystalline cellulose, low moisture and packed into AI/AI bag. The bag was put into the stress testing chamber for 7 days at 80°C and 75% relative humidity. After 7 days the amount of total impurities were measured by HPLC in order to analyze chemical purity. In addition, in order to analyze physical stability of polymorph, XRPD analysis was performed. mg/bag
- Example 2 By comparing Comparative Example 2 with Example 2 it is clear that ixazomib citrate form 3 performs considerably better than ixazomib citrate form 1. Ixazomib citrate form 3 exhibits considerably better chemical purity than ixazomib citrate form 1 (1.4% vs. 1.7%, respectively) and the form is polymorphically stable. Moreover, using of low moisture excipient provides chemically and physically stable product based on comparing XRPD and HPLC data in Example 1 and 2.
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a pharmaceutical formulation containing ixazomib citrate in crystalline form 3 of formula I, wherein form 3, compared to the hitherto known form 1, is a polymorphically more stable form, which makes it more suitable for a pharmaceutical formulation containing besides ixazomib citrate of form 3 also other acceptable excipients. The pharmaceutical formulation can be in the form of capsules and is packed in a gas-tight AI/AI blister pack to maintain its stability.
Description
A formulation of ixazomib citrate form 3
Field of the Invention The invention relates to a pharmaceutical formulation of the novel polymorphic form 3 of ixazomib citrate of formula I:
I (Form 3)
Form 3, as compared to the hitherto known form 1 of ixazomib citrate of formula I, disclosed in the patent WO 2009/154737, has turned out to be a polymorphically more stable form, which also makes it more suitable for use in ixazomib citrate formulation.
Background Art
Ixazomib is a novel member of the group of proteasome inhibitors with a structure belonging to the group of peptide boronic acids, now also known under the commercial name of Ninlaro. Ixazomib citrate is currently approved for use in combination with lenalidomide and dexamethasone, intended for the treatment of patients with multiple myeloma after at least one prior therapy.
An advantage of ixazomib citrate, compared e.g. to bortezomib is that thanks to stabilization of the boronic acid in the form of a mixed ester-anhydride with citric acid the substance can also be administered in the oral form. Thus, ixazomib citrate is the first and so far the only orally administered drug of this kind, used for the treatment of multiple myeloma.
Boronic acids are sometimes difficult to prepare in the pure form. In conditions that are favorable for dehydration, boronic acids form cyclic anhydrides and are often sensitive to light. Therefore, boronic acids are advantageously stabilized with a complexing agent, e.g. an a- or β-hydroxy acid (WO2009/154737), or by preparation
of precursors with azanediylbis alcohols (WO 2012/177835, WO 2011/087822A1), which enhances their stability and makes it possible to prepare a drug form, suitable for oral administration. Ixazomib citrate and a method of its preparation was first described in the patent application WO 2009/154737.
A preparation method of isomers of ixazomib citrate form 1 or 2 from boroxine III is described in the patent application WO 2009/154737 and is illustrated by Diagram 1. Di ram 1
II (form 2)
Boroxine III, or its free boronic acid is subjected to a reaction with citric acid in a solvent at an elevated temperature; after cooling, the crystallized product is isolated by filtering. Depending on the execution conditions of this reaction, form 1 of formula I, or form 2 of formula II can be obtained, both characterized by NMR, MS, X-ray powder diffraction and the DSC (differential scanning calorimetry) and TGA (thermogravimetric analysis) methods
If after a reaction of boroxine III with citric acid in ethyl acetate at 74°C the reaction mixture is subjected to uncontrolled cooling, it may lead to formation of the 5-member isomeric form 1 (melting point 198.8°C) while controlled cooling of the reaction mixture to the laboratory temperature or to 40°C leads to the formation of the more stable isomeric form 2 (melting point 219.9°C). Form 2 can also be prepared through a reaction of the compound III with citric acid and crystallization from various solvents
(tetrahydrofuran, acetonitrile, methyl /so-butyl ketone, 2-methyltetrahydrofuran, acetone) and subsequent addition of the ethyl acetate as an antisolvent.
Disclosure of the Invention
The principle of the invention is a pharmaceutical formulation containing ixazomib citrate in crystalline form 3 as the active ingredient and at least one pharmaceutically acceptable auxiliary substance. Form 3 is a new polymorphic form of ixazomib citrate of formula I and exhibits the characteristic reflections in an X-ray powder patterns with the use of CuKa radiation: 5.4; 10.9; 12.4; 18.7 and 22.6 ± 0.2° 2-theta.
These characteristic and the other measured reflections are presented in Table 1. The X-ray pattern is included in the Appendix as Figure 1.
Table 1 : Table of characteristic peaks:
Pos. Rel. Int.
[°2Th.] d [A] [%]
5.44 16.226 100.0
7.47 11.824 6.1
10.91 8.106 29.6
12.06 7.334 6.7
12.44 7.112 15.5
16.42 5.393 6.4
17.19 5.153 8.3
18.68 4.746 29.2
19.02 4.663 10.2
19.46 4.557 7.5
20.77 4.274 10.4
21.47 4.135 5.8
21.98 4.041 4.1
22.60 3.931 22.2
23.54 3.776 7.3
Pos. Rel. Int.
[°2Th.] d [A] [%]
24.31 3.659 3.1
25.14 3.540 6.3
25.64 3.471 4.0
26.34 3.380 8.5
26.63 3.345 6.6
28.06 3.178 2.9
29.56 3.019 2.2
31.13 2.871 2.7
33.27 2.691 4.2
34.31 2.611 2.7
34.89 2.570 6.9
The new form 3 of ixazomib citrate of formula I proved to be a chemically and polymorphically stable form of isomer I of ixazomib citrate in pre-formulation experiments. Contrary to that, form 1 of ixazomib citrate of formula I, indicated in the patent WO 2009/154737, turned out to be polymorphically unstable under certain conditions and its conversion to ixazomib citrate of form 2 of formula II was observed. In a preferred embodiment, the pharmaceutical formulation according to the invention is packed in air-tight packages as an AI/AI blister pack.
The excipients are preferably processed in such a way as to have a low content of moisture, e.g. less than 4%.
Detailed description of the Invention
The present invention relates to preparation of the solid pharmaceutical dosage form comprising ixazomib citrate in crystalline form 3, which can preferably be packed into a gas non-permeable packaging.
One embodiment of the present invention comprises a pharmaceutical formulation with ixazomib citrate form 3 with an acceptable stability. Pharmaceutical formulations
are preferably packed into a gas non-permeable packaging. Preferred gas non- permeable packaging is AI/AI blister.
A pharmaceutical formulation comprising ixazomib citrate form 3 typically comprises one or more excipients. Though in general various excipients could be used, it is especially favorable to use excipients with low amount of residual water. In this invention an excipient with low amount of residual water is defined as an excipient, which contains not more than 4% w/w of water. The water content can be measured by a loss on drying apparatus. An example of such apparatus is for example from the firm Sartorius. Amount of water is measured at conditions 105°C for 10 minutes.
One of the excipients, which may be used to prepare a pharmaceutical formulation comprising ixazomib citrate form 3 is a filler. Suitable fillers that can be used in preparation of pharmaceutical formulation of ixazomib citrate form 3 may be selected from, but not restricted to calcium hydrogen phosphate, microcrystalline cellulose, monosaccharides, oligosaccharides and sugar alcohols like glucose, fructose, saccharose, lactose monohydrate, lactose anhydrous, mannitol, erythritol, sorbitol, maltitol, xylitol and lactitol, compressible sugar and mixtures thereof. Preferred fillers are microcrystalline cellulose, calcium hydrogen phosphate anhydrous, lactose and mannitol. Most preferred are mannitol and a low moisture microcrystalline cellulose containing no more than 4% w/w of water. The amount of filler used to prepare the composition comprising ixazomib citrate form 3 may comprise 40 - 99% in such a way that the sum of API, filler and all other excipients reaches 100% of the final composition.
The other excipient, which may be used to prepare a pharmaceutical formulation comprising ixazomib citrate form 3 is glidant. Suitable glidants that can be used in preparation of pharmaceutical formulation of ixazomib citrate form 3 may be selected from, but not restricted to magnesium silicate, magnesium oxide, magnesium trisilicate, colloidal silicon dioxide, hydrophobic colloidal silica, sodium stearate, talc and mixtures thereof. Preferred glidants are colloidal silicon dioxide and talc. The amount of glidant used to prepare the composition comprising ixazomib citrate form 3 may be 0.1 - 0%.
The other excipient, which may be used to prepare a pharmaceutical formulation comprising ixazomib citrate form 3 is lubricant. Suitable lubricants that can be used in preparation of pharmaceutical formulation of ixazomib citrate form 3 may be selected from, but not restricted to hydrogenated castor oil, light mineral oil, myristic acid, palmitic acid, zinc stearate, stearic acid, hydrogenated vegetable oil, polyethylene glycol, glyceryl monostearate, glyceryl palmitostearate, sodium lauryl sulfate, sodium stearyl fumarate, magnesium stearate and mixtures thereof. Preferred lubricants are stearic acid and magnesium stearate. The amount of lubricants used to prepare the composition comprising ixazomib citrate form 3 may be 0.1 - 10%.
In addition to the above stated, a pharmaceutical formulation comprising ixazomib citrate form 3 may include also other excipients. Examples of other excipients that can be used in preparation of pharmaceutical formulation of ixazomib citrate form 3 may be selected from binders, surfactants, disintegrants etc.
A pharmaceutical formulation comprising ixazomib citrate form 3 is typically an encapsulated product. Suitable capsule shell materials used for encapsulation of pharmaceutical formulation of ixazomib citrate form 3 may be selected from both animal as well as vegetable origin. Some non-binding examples of capsule shell materials of animal origin may be selected from animal protein materials like gelatin. Some non-binding examples of capsule shell materials of vegetable origin may be selected from plant polysaccharides like hydroxypropyl methylcellulose, carrageenan and modified forms of starch.
Brief description of the Drawings
Figure 1 : X-ray powder pattern of ixazomib citrate of form 3.
Figure 2: DSC record of ixazomib citrate of form 3.
Figure 3: TGA record of ixazomib citrate of form 3.
Examples
HPLC purity
HPLC column: Ascentis Express C-18 100 x 4.6 mm, 2.7 pm
Mobile phase: A 0.05 mol/l acetic acid, pH adjusted with an ammonia solution to 5.0
B: methanol
Gradient- Time Flow % A % B
(min) (ml/min)
0 0.8 89 11
14 0.8 5 95
15 0.8 5 95
16 0.8 89 11
20 0.8 89 11
Analysis time: 20 minutes
Injected quantity: 5 μΙ
Sample 15°C
temperature:
Column 25°C
temperature:
Detection: UV 230 nm
Sample 5 mg of a sample of the substance is dosed into a 10ml preparation: volumetric flask and dissolved in 2 ml of methanol. The flask is filled with water up to the line and stirred.
Analytes: Compound: Retention time (min) Negligibility threshold
TBTU 2.9 0.03%
DCBA 5.0 0.03%
IXA-2 5.2 0.03%
IXA-2 amide 6.3 0.03%
N7 10.1 0.03%
X-ray powder diffraction
The diffractogram was obtained using an XPERT PRO MPD PANalytical powder diffractometer, used radiation CuKa (λ = 0.1542 nm (1.542 A)), excitation voltage: 45 kV, anode current: 40 mA, measured range: 2 - 40° 2Θ, increment: 0.02° 2Θ at the reflection dwell time of 300 s. For the correction of the primary array 0.02 rad Soller slits, a 10 mm mask and a 1/4° fixed anti-dispersion slit were used. The irradiated area of the sample is 10 mm, programmable divergence slits were used. For the correction of the secondary array 0.02 rad Soller slits and a 5.0 anti-dispersion slit were used. The measurement was carried out with a flat sample applied onto a Si plate.
The records of the differential scanning calorimetry (DSC) were measured using a DSC Pyris 1 device made by the company Perkin Elmer. The sample charge in a standard Al pot was between 3 and 4 mg and the heating rate was 10°C/min. The temperature program that was used consists of 1 min of stabilization at the temperature of 20°C and then of heating up to 250°C at the heating rate of 10°C/min. As the carrier gas 4.0 N2 was used at the flow of 20 ml/min.
The records of the thermogravimetric analysis (TGA) were measured using a TGA 6 device made by the company Perkin Elmer. The sample charge in a corundum pot was 15-17 mg and the heating rate was 10°C/min. The temperature program that was used consists of 1 minute's stabilization at the temperature of 20°C and then of heating up to 300°C at the heating rate of 10°C/min. As the carrier gas 4.0 N2 was used at the flow of 20 ml/min.
Preparative example - preparation of ixazomib citrate of form 3
3.00 g (6.06 mmol) of 2,5-dichloro-N-[2-({(1 R)-3-methyl-1-[(3aS,4Sl6S,7aR)-3a)5I5- trimethylhexahydro-4,6-methano-1 ,3,2-benzodioxaborol-2-yl]butyl}amino)-2- oxoethyl]benzamide of formula V, 0.41 g (6.67 mmol) of boric acid and 1.28 g (6.67 mmol) of citric acid are dosed into a flask. The mixture is stirred in 15 ml of acetone at the room temperature for 22 h. 50 ml of ethyl acetate is added to the mixture. After removal of a part of the solvent (15 ml) by distillation and spontaneous cooling of the reaction mixture, ixazomib citrate of formula I is obtained by aspiration. After drying in a vacuum drier (16 h at 40°C) the yield of the reaction is 91% wt. and HPLC purity of the product 98.9%.
The XRPD pattern is shown in Fig. 1 , the characteristic peaks are presented in Table 1.
The DSC record contains an endothermic curve that corresponds to the melting point Tonset = 212.2°C. The record is shown in Fig. no. 2 in the Appendix.
The TGA record indicates a weight loss in the temperature range of 20 to 200°C of approx. 1.3%.
The record is shown in Fig. no 3 in the Appendix.
Comparative Example 0
Ixazomib citrate form 1 was mixed with microcrystalline cellulose, standard moisture and packed into a standard polyethylene (PE) bag. The bag was put into the stress testing chamber for 7 days at 80°C and 75% relative humidity. After 7 days the amount of total impurities were measured by HPLC in order to analyze chemical purity. In addition, in order to analyze physical stability of polymorph, XRPD analysis was performed.
The standard polyethylene bag did not exhibit enough protection. High amount of impurities were formed (12.1%) and in addition, polymorphic form changed from form 1 into form 2. Microcrystalline cellulose, standard moisture in combination with standard polyethylene packaging does not exhibit adequate protection of ixazomib citrate.
Comparative Example 1
Ixazomib citrate form 1 was mixed with microcrystalline cellulose, standard moisture and packed into AI/AI bag. The bag was put into the stress testing chamber for 7 days at 80°C and 75% relative humidity. After 7 days the amount of total impurities were measured by HPLC in order to analyze chemical purity. In addition, in order to analyze physical stability of polymorph, XRPD analysis was performed. Significant chemical degradation and polymorphic transformation were observed similar as the same formulation mixture packed in PE.
mg/bag
Ixazomib citrate form 1 4.00
Microcrystalline cellulose, standard moisture 86.00
Packaging AI/AI bag
Total impurities (HPLC) 8.6%
Form of Ixazomib citrate (XRPD) form 2
Example 1 Ixazomib citrate form 3 was mixed with microcrystalline cellulose, standard moisture and packed into AI/AI bag. The bag was put into the stress testing chamber for 7 days at 80°C and 75% relative humidity. After 7 days the amount of total impurities were measured by HPLC in order to analyze chemical purity. In addition, in order to analyze physical stability of polymorph, XRPD analysis was performed.
By comparing Comparative Example 1 with Example 1 it is clear that ixazomib citrate form 3 performs considerably better than ixazomib citrate form 1. Ixazomib citrate form 3 exhibits considerably better chemical purity than ixazomib citrate form 1 (5.5% vs. 8.6%, respectively). In addition, ixazomib citrate form 3 does not change its physical form, while ixazomib citrate form 1 converts to form 2.
In addition, by comparing those results with Comparative example 0, it can also be noticed that the use of the AI/AI bag significantly improves stability of ixazomib citrate.
Comparative Example 2
Ixazomib citrate form 1 was mixed with microcrystalline cellulose, low moisture and packed into AI/AI bag. The bag was put into the stress testing chamber for 7 days at 80°C and 75% relative humidity. After 7 days the amount of total impurities were measured by HPLC in order to analyze chemical purity. In addition, in order to analyze physical stability of polymorph, XRPD analysis was performed. Comparing HPLC and XRPD data from table below with those for comparative example 1 , it seems that using of low moisture microcrystalline cellulose provides formulation with better chemical and physical stability
Example 2 Ixazomib citrate form 3 was mixed with microcrystalline cellulose, low moisture and packed into AI/AI bag. The bag was put into the stress testing chamber for 7 days at 80°C and 75% relative humidity. After 7 days the amount of total impurities were measured by HPLC in order to analyze chemical purity. In addition, in order to analyze physical stability of polymorph, XRPD analysis was performed.
mg/bag
Ixazomib citrate form 3 4.00
Microcrystalline cellulose, low moisture 86.00
Packaging AI/AI bag
Total impurities (HPLC) 1.4%
Form of Ixazomib citrate (XRPD) form 3
By comparing Comparative Example 2 with Example 2 it is clear that ixazomib citrate form 3 performs considerably better than ixazomib citrate form 1. Ixazomib citrate form 3 exhibits considerably better chemical purity than ixazomib citrate form 1 (1.4% vs. 1.7%, respectively) and the form is polymorphically stable. Moreover, using of low moisture excipient provides chemically and physically stable product based on comparing XRPD and HPLC data in Example 1 and 2.
Example 3
Form 3 of ixazomib citrate was stirred either with mannitol or with microcrystalline cellulose with a low moisture content for 15 minutes. Then, talc was added and the mixture was stirred for another 10 minutes. Finally, magnesium stearate was added and the mixture was stirred for another 3 minutes so that a mixture for processing into capsules could be prepared. The prepared mixture was subsequently manually processed into gelatin capsules of size 4. The gelatin capsules were packed in AI/AI blister packs. mg mg mg mg mg mg in 1 in 1 in 1 in 1 in 1 in 1 capsule capsule capsule capsule capsule capsule
Form 3 of ixazomib
4.00 4.00 3.00 3.00 2.3 2.3 citrate
Mannitol 84.00 85.00 85.70
Microcrystalline
84.00 85.00 85.70 cellulose, low moisture
Talc 1.00 1.00 1.00 1.00 1.00 1.00
Magnesium stearate 1.00 1.00 1.00 1.00 1.00 1.00
Total 90.00 90.00 90.00 90.00 90.00 90.00
Gelatin capsules of
size 4
Blister pack material AI/AI AI/AI AI/AI AI/AI AI/AI AI/AI
Claims
A pharmaceutical formulation containing the active ingredient ixazomib citrate in crystalline form 3, exhibiting the following characteristic reflections in an X-ray pattern measured with the use of CuKa radiation: 5.4; 10.9; 12.4; 18.7 and 22.6 ± 0.2° 2-theta, and at least one pharmaceutically acceptable excipient.
The pharmaceutical formulation according to claim 1 , characterized in that it is packed in gas-tight packages.
The pharmaceutical formulation according to claim 2, characterized in that it is packed in AI/AI blister packs.
The pharmaceutical formulation according to any one of the preceding claims, characterized in that one or more excipients contain less than 4% wt. of water.
The pharmaceutical formulation according to claim 4, characterized in that the filler is selected from a sugar alcohol, microcrystalline cellulose with a low moisture content or their mixture.
The pharmaceutical formulation according to claim 5, characterized in that mannitol is selected as the sugar alcohol.
The pharmaceutical formulation according to claim 4 or 5, characterized in that it contains at least one other excipient.
The pharmaceutical formulation according to claim 7, characterized in that the other excipients are selected from a lubricant, glidant, disintegrant, binder, or their combination.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CZPV2016-204 | 2016-04-08 | ||
CZ2016-204A CZ2016204A3 (en) | 2016-04-08 | 2016-04-08 | Formulation of ixazomib citrate of form 3 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017174046A1 true WO2017174046A1 (en) | 2017-10-12 |
Family
ID=58668693
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CZ2017/000022 WO2017174046A1 (en) | 2016-04-08 | 2017-04-07 | A formulation of ixazomib citrate form 3 |
Country Status (2)
Country | Link |
---|---|
CZ (1) | CZ2016204A3 (en) |
WO (1) | WO2017174046A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117964650A (en) * | 2024-03-28 | 2024-05-03 | 成都硕德药业有限公司 | Preparation method of citric acid Sha Zuomi |
WO2024097905A1 (en) | 2022-11-02 | 2024-05-10 | Celgene Corporation | Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009154737A1 (en) | 2008-06-17 | 2009-12-23 | Millennium Pharmaceuticals, Inc. | Boronate ester compounds and pharmaceutical compositions thereof |
WO2011087822A1 (en) | 2009-12-22 | 2011-07-21 | Cephalon, Inc. | Proteasome inhibitors and processes for their preparation, purification and use |
WO2012177835A1 (en) | 2011-06-22 | 2012-12-27 | Cephalon, Inc. | Proteasome inhibitors and processes for their preparation, purification and use |
WO2016155684A1 (en) * | 2015-04-03 | 2016-10-06 | Zentiva, K.S. | A process of preparing ixazomib citrate |
WO2016165677A1 (en) * | 2015-04-15 | 2016-10-20 | Zentiva, K.S. | New forms of ixazomib citrate |
-
2016
- 2016-04-08 CZ CZ2016-204A patent/CZ2016204A3/en unknown
-
2017
- 2017-04-07 WO PCT/CZ2017/000022 patent/WO2017174046A1/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009154737A1 (en) | 2008-06-17 | 2009-12-23 | Millennium Pharmaceuticals, Inc. | Boronate ester compounds and pharmaceutical compositions thereof |
WO2011087822A1 (en) | 2009-12-22 | 2011-07-21 | Cephalon, Inc. | Proteasome inhibitors and processes for their preparation, purification and use |
WO2012177835A1 (en) | 2011-06-22 | 2012-12-27 | Cephalon, Inc. | Proteasome inhibitors and processes for their preparation, purification and use |
WO2016155684A1 (en) * | 2015-04-03 | 2016-10-06 | Zentiva, K.S. | A process of preparing ixazomib citrate |
WO2016165677A1 (en) * | 2015-04-15 | 2016-10-20 | Zentiva, K.S. | New forms of ixazomib citrate |
Non-Patent Citations (1)
Title |
---|
HILFIKER R (EDITOR) ED - HILFIKER R: "Polymorphism in the Pharmaceutical Industry", 1 January 2006, 20060101, PAGE(S) 1 - 19, ISBN: 978-3-527-31146-0, XP002528052 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024097905A1 (en) | 2022-11-02 | 2024-05-10 | Celgene Corporation | Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy |
CN117964650A (en) * | 2024-03-28 | 2024-05-03 | 成都硕德药业有限公司 | Preparation method of citric acid Sha Zuomi |
CN117964650B (en) * | 2024-03-28 | 2024-06-07 | 成都硕德药业有限公司 | Preparation method of citric acid Sha Zuomi |
Also Published As
Publication number | Publication date |
---|---|
CZ2016204A3 (en) | 2017-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3277688B1 (en) | Co-crystals of ibrutinib | |
US20220267299A1 (en) | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer | |
JP2008509953A (en) | 4-[[(7R) -8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-4-6-oxo-2-piperidinyl] amino] -3-methoxy-N- ( 1-methyl-4-piperidinyl) benzamide hydrates and polymorphs, processes for their preparation and their use as drugs | |
WO2011095059A1 (en) | Polymorphs of dasatinib, preparation methods and pharmaceutical compositions thereof | |
US9603804B2 (en) | Solid pharmaceutical composition | |
JP2015525227A (en) | Multi-component crystals comprising dasatinib and a selected co-crystal former | |
EP3243824A1 (en) | Solid forms of ibrutinib free base | |
JP6716023B2 (en) | Crystalline form of androgen receptor antagonist, method for producing the same and use thereof | |
US20030191347A1 (en) | Venlafaxine base | |
US20200148626A1 (en) | New Crystalline Forms of Vilanterol Trifenatate and Processes for Their Preparation | |
WO2012017028A1 (en) | A novel crystalline compound comprising saxagliptin and phosphoric acid | |
EP3530271A1 (en) | Crystalline form ii of dextral oxiracetam, preparation method therefor and use thereof | |
EP3808742A1 (en) | Polymorph of selinexor | |
WO2017174046A1 (en) | A formulation of ixazomib citrate form 3 | |
TWI492919B (en) | Process for the production of ralfinamide salts substantially free from impurities having genotoxic effects | |
EA031581B1 (en) | Solid form of anamorelin monohydrochloride having reduced chloride content | |
JP2017524004A (en) | Bicomponent crystals of bismodegib and selected co-crystal formers or solvents | |
US10053427B2 (en) | Crystalline forms of cabozantinib phosphate and cabozantinib hydrochloride | |
KR102447769B1 (en) | The crystalline form of valbenazine tosylate and its preparation and use | |
EP2938603A1 (en) | Cobicostat dichlohydrate salt | |
US20080234286A1 (en) | Stable amorphous imatinib mesylate and production process therefor | |
US8754129B2 (en) | Crystalline vorinostat form VI | |
EP3587421A1 (en) | Crystalline forms of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-alpha]pyrazin-1-yl-n-(pyridin-2-yl)benzamide | |
WO2019099761A1 (en) | Solid state forms of elafibranor | |
US9981912B2 (en) | Cocrystal of lorcaserin, preparation methods, pharmaceutical compositions and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17721043 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17721043 Country of ref document: EP Kind code of ref document: A1 |